The pharmaceutical pipeline is gaining momentum, led by many first-time launchers. But the reality is companies spend >$200MM over three years leading up to launch, and 66% of drugs still don’t meet launch expectations.
This looming risk, echoed by general industry pressures, leaves developers and investors alike looking for more advanced commercialisation options that effectively maximize their pipelines, minimize risk, optimize investment, and increase the speed to market.
Join us for this live session as we discuss:
- Trends in US Biopharma, MedTech and DTx launches
- Explore differences between commercialisation models: launching with EVERSANA, traditional licensing or launching on your own
- Optimizing launch sequence across markets in Europe and globally
Date: Wednesday, March 2nd 2022
Time: 9:00 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
Program
| 9:00 | Networking, registration and light breakfast |
| 9:30 | Welcome David Munis Zepernick, Head of Business Development and Public Affairs, Medicon Valley Alliance Stephen Brugger, Executive Director, AmCham |
| 9:35 | Next Generation Commercialization for Life Sciences Launching in the USA EVERSANA |
| 10:20 | Q&A |
| 10:30 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Mike Ryan, Executive Vice President, Europe
With more than 25 years of experience in the life science industry, Mike has held global leadership positions in both clinical development and life-sciences software companies. Given this experience, he is highly experienced in the use of technology and understands its impact in simplifying the process of developing and delivering novel therapies and making them more accessible to patients around the world. He has worked with many biotech and pharmaceutical companies to develop clinical pathways that deliver upon the ultimate commercial goals required to ensure success for all stakeholders. Mike speaks at many global industry events to promote the idea of innovation in healthcare and to encourage a greater level of partnership between healthcare stakeholders.
|
 |
Rohit Sood, Executive Vice President, COMPLETE Commercialization
Rohit is helping EVERSANA disrupt the life sciences industry with innovative commercialisation solutions. As a strategy and operations professional, he has served as both an advisor and global strategy leader, driving top-line business growth and identifying significant operational efficiencies in PE-backed, startup and publicly listed organizations. He has advised senior management and CEOs of global life sciences companies on critical topics, including therapeutic area growth strategy, R & D, licensing, go-to-market approaches, launch/commercial excellence and commercial models. Rohit holds an MBA from Rutgers Business School and an MS in telecommunications from Pace University.
|
 |
Franjo Hanzl, Vice President Commercial Development Europe
As a leader of the commercial team in Europe, Franjo helps clients solve complex industry challenges while supporting streamlined commercialisation strategies that get innovative therapies to patients across borders. He joined EVERSANA with more than 25 years of experience in the life sciences industry and has led global launches across six continents in his career. Franjo has extensive expertise in marketing, business development, and pharmaceutical partnership and alliance management through his work with branded and generic pharma in Europe, which also provides him with a deep knowledge of the pricing landscape. Franjo holds a master’s degree in pharmacy from the University of Zagreb in Croatia.
|
|
In collaboration with | ||
 |
 |
 |